


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(currently amended)** A compound of formula I and pharmaceutically acceptable salts thereof:



wherein

A is O, CO, S, NR^d, or CR^bR^c;

D is COR⁴, C(O)NR^dR⁴, C(O)OR⁴, SO₂R⁴, SO₂NR^dR⁴;

X, Y and Z are independently a ring carbon atom or a ring nitrogen atom, with the proviso that 0-3 X, 0-3 Y and 0-3 Z are ring nitrogen atoms;

R^{1a} and R^{1b} are independently selected from (1) H, (2) halogen, (3) C₁₋₆alkyl optionally substituted with 1-5 groups independently selected from halogen, nitro, cyano, COR^a, CO₂R^a, C(O)NR^dRe, OR^a, OC(O)R^a, SR^a, SO₂R^f, S(O)R^f, NR^dRe, NR^dC(O)R^a and NR^dSO₂R^f, (4) C(O)R^a, (5) CO₂R^a, (6) C(O)NR^dRe, (7) OR^a, (8) OC(O)R^a, (9) OC(O)NR^dRe, (10) NR^dRe, (11) NR^dC(O)R^a, (12) NR^dC(O)OR^a, (13) NR^dC(O)NR^dRe, (14) NR^dSO₂R^f, (15) SR^a, (16) S(O)R^f, (17) SO₂R^f, (18) SO₂NR^dRe, (19) CN, (20) NO₂, (21) optionally substituted aryl, (22) optionally substituted heteroaryl, (23) optionally substituted heterocyclyl, (24) optionally substituted aryl-C₁₋₆alkyl, (25) optionally substituted heteroaryl-C₁₋₆alkyl, and (26) optionally substituted heterocyclyl-C₁₋₆alkyl; wherein the substituents for aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^a, NR^dRe, NR^dC(O)R^a, NR^dSO₂R^f, OC(O)R^a, NR^dC(O)₂R^a, SR^a,

SO₂R^f, oxo (for heterocyclyl and heterocyclylalkyl), C(O)R^a, C(O)₂R^a, C₁₋₄ alkyloxy, aryl, aryl-C₁₋₄alkyl, heteroaryl, heteroaryl-C₁₋₄alkyl, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, or

R^{1a}, R^{1b} and adjacent carbon atoms to which they are attached together form a saturated, partially unsaturated or aromatic 5- or 6-membered ring containing 0 to 2 heteroatoms selected from N, N-R^g, O and S;

R^{2a} and R^{3a} are independently selected from (1) H, (2) halogen, (3) OR^a, (4) NR^dRe, (5) CN, (6) NO₂, (7) CO₂R^a, (8) COR^a, and (9) C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms,

R⁴ is selected from (1) C₁₋₆alkyl substituted with 1 to 5 halogen atoms, OR^a, NR^dRe or C(O)NR^dRe in which, for these two occurrences, R^d and R^e together complete a 4- to 8-membered ring optionally containing an additional heteroatom selected from NR^g, O, S, and SO₂, and said ring being optionally fused to a benzene or a 5- or 6-membered heteraromatic ring, and optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, nitro, OR^g, oxo, C₃₋₆ cycloalkyl, aryl, heteroaryl, NR^gR^g, NR^gCOR^g, NR^gCO₂R^g and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms; (2) optionally substituted heteroaryl; (3) optionally substituted heteroaryl-C₁₋₄alkyl; (4) optionally substituted heterocyclyl; (4) optionally substituted heterocyclyl-C₁₋₄alkyl; wherein the substituents for heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^a, NR^dRe, NR^dC(O)R^a, NR^dSO₂R^f, OC(O)R^a, NR^dC(O)₂R^a, SR^a, SO₂R^f, oxo (for heterocyclyl and heterocyclylalkyl), C(O)R^a, C(O)₂R^a, C₁₋₄ alkyloxy, aryl, aryl-C₁₋₄alkyl, heteroaryl, heteroaryl-C₁₋₄alkyl, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms; (1) H, (2) C₁₋₆alkyl optionally substituted with 1 to 5 groups independently selected from halogen, nitro, cyano, C₃₋₆cycloalkyl, COR^a, CO₂R^a, C(O)NR^dRe, OR^a, OC(O)R^a, SR^a, SO₂R^f, S(O)R^f, NR^dRe, NR^dC(O)R^a, NR^dSO₂R^f, and NR^dC(O)₂R^a; (3) optionally substituted C₃₋₆cycloalkyl; (4) COR^a; (5) COOR^a; (6) optionally substituted aryl; (7) optionally substituted heteroaryl; (8) optionally substituted heterocyclyl; (9) optionally substituted aryl-C₁₋₆alkyl; (10) optionally substituted heteroaryl-C₁₋₆alkyl; and (11) optionally substituted heterocyclyl-C₁₋₆alkyl; wherein the substituents for cycloalkyl, aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^a, NR^dRe, NR^dC(O)R^a, NR^dSO₂R^f, OC(O)R^a, NR^dC(O)₂R^a, SR^a, SO₂R^f, oxo (for heterocyclyl and heterocyclylalkyl), C(O)R^a, C(O)₂R^a, C₁₋₄ alkyloxy, aryl

~~optionally substituted with 1 or 2 halogen atoms, aryl-C₁₋₄alkyl, heteroaryl, heteroaryl-C₁₋₄alkyl, C₃₋₆cycloalkyl and C₁₋₄alkyl optionally substituted with 1 to 5 halogen atoms;~~

~~R^{4'} is a group selected from R⁴ except R^{4'} is not H; ———~~

R^a is (1) H, (2) C₁₋₆ alkyl optionally substituted with 1 to 5 groups independently selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy and C₃₋₆ cycloalkyl, (3) C₃₋₆ cycloalkyl, (4)

optionally substituted aryl, (5) optionally substituted heteroaryl, (6) optionally substituted heterocyclyl, (7) optionally substituted aryl-C₁₋₆alkyl, (8) optionally substituted heteroaryl-C₁₋₆alkyl, and (9) optionally substituted heterocyclyl-C₁₋₆alkyl; wherein the substituents for aryl, heteroaryl, heterocyclyl, aralkyl, heteroaralkyl and heterocyclylalkyl are 1 to 3 groups independently selected from halogen, cyano, nitro, OR^g, NR^dRe, NR^dC(O)R^g, NR^dSO₂R^f, OC(O)R^g, NR^dC(O)₂R^g, SR^g, SO₂R^f, oxo (for heterocyclyl and heterocyclylalkyl), C(O)R^g_a, C(O)₂R^g, C₁₋₄ alkyloxy, aryl, aryl-C₁₋₄alkyl, heteroaryl, heteroaryl-C₁₋₄alkyl, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms;

R^b and R^c are independently selected from H, halogen, or C₁₋₄alkyl optionally substituted with 1 to 5 halogen atoms;

R^d and R^e are independently selected from (1) H, (2) C₁₋₄alkyl, optionally substituted with 1 to 5 groups independently selected from halogen, amino, mono-C₁₋₄alkylamino, di-C₁₋₄alkylamino, and SO₂R^f, (3) aryl-C₁₋₆alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (4) heteroaryl-C₁₋₆alkyl optionally substituted with 1 to 3 groups selected from halogen, cyano, nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, and (5) C₃₋₆ cycloalkyl, or

R^d and R^e, or R^d and R⁴, ~~or R^d and R^{4'}~~, together with the atom or atoms to which they are attached, complete a 4- to 8-membered saturated, partially saturated or aromatic ring optionally containing 1 to 3 heteroatoms independently selected from N, NR^g, O, S, and SO₂, and said ring being optionally fused to a benzene or a 5- or 6-membered heteraromatic ring, and optionally substituted with 1 to 3 substituents independently selected from halogen, cyano, nitro, OR^g, oxo, C₃₋₆ cycloalkyl, aryl, aryl-C₁₋₄alkyl, heteroaryl, NR^gR^g, NR^gCOR^g, NR^gCO₂R^g and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms;


R^f is selected from (1) C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms, (2) C₁₋₄ alkyloxy, and (3) aryl optionally substituted with 1 to 3 groups selected from halogen, cyano,

nitro, OH, C₁₋₄ alkyloxy, C₃₋₆ cycloalkyl and C₁₋₄ alkyl optionally substituted with 1 to 5 halogen atoms;

R_g is selected from (1) H, (2) C₁₋₄alkyl, (3) aryl, (4) aryl-C₁₋₆alkyl, (5) C(O)₂C₁₋₄alkyl and (6) C(O)C₁₋₄alkyl;

~~with the proviso that when each occurrence of X, Y and Z is a ring carbon atom, R^{1a} and R^{1b} are each hydrogen or chlorine, and R^{2a} and R^{2b} are each hydrogen, then D is not NHC(O)C₁₋₆alkyl;~~

~~with the further proviso that the following compound is excluded:~~




2. **(original)** A compound of Claim 1 wherein A is C(O) or O.


3. **(canceled)**

4. **(original)** A compound of Claim 1 wherein each occurrence of Y and Z represents a ring carbon atom, and one X is a ring carbon or nitrogen atom and the others are ring carbon atoms.

5. **(canceled)**

6. **(currently amended)** A compound of Claim 1 having the formula Ia(1) and pharmaceutically acceptable salts thereof:





Ia(1)

wherein

A is O or C(O);

one of X is a ring carbon or nitrogen atom, and the others are ring carbon atoms;

D is C(O)R⁴, C(O)NR^dR⁴ or C(O)OR⁴;

R^{1a} and R^{1b} are independently selected from hydrogen, halogen, C₁-4alkyl, cyano, SR^a, OR^a and CF₃;

R^{2a} and R^{3a} are independently H or halogen;


R⁴ is selected from (1) C₁-4alkyl substituted with one to 5 groups independently selected from halogen, C₃-6 cycloalkyl, NR^dRe, NR^dC(O)R^a, C(O)NR^dRe, C(O)OR^a, and OR^a; (2) C₃-6cycloalkyl; (3) phenyl; (4) phenyl-C₁-4alkyl; (5) optionally substituted heteroaryl; (6) optionally substituted heteroaryl-C₁-4alkyl; (7) optionally substituted heterocyclyl; and (8) optionally substituted heterocyclyl-C₁-4alkyl; wherein heteroaryl, including as part of heteroarylalkyl, is selected from benzofuranyl, pyrazolo[1,5-a]pyrimidinyl, 1-azaindoliziny, s-triazolo[1,5-a]pyrimidinyl, thieno[3,2-b]pyridinyl, isoxazolyl, pyrazinyl, pyrazolyl, pyrimidinyl, benzisoxazolyl, pyridyl, indolyl, benzimidazolyl, benzthiazolyl and imidazo[2,1-b]thiazolyl; heterocyclyl, including as part of heterocyclylalkyl, is selected from morpholinyl, tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl and imidazolidinyl; the substituents for heteroaryl is 1 or 2 groups independently selected from C₁-4alkyl, C₃-6cycloalkyl, and OR^a; and the substituents for heterocyclyl is 1 to 3 groups independently selected from oxo and C₁-4alkyl,

R^a and R^d are as defined in Claim 1.

7. (canceled)

8. **(currently amended)** A compound of Claim 7-6 wherein R^4 is selected from (1) C_1 -4alkyl substituted with NR^dRe or $C(O)NR^dRe$ where for both groups R^d and Re , together with the nitrogen atom to which they are attached, complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR^g , O, S and SO_2 , and wherein said substituent is 1 or 2 groups independently selected from OR^a , halogen, C_1 -4alkyl and oxo; (2) optionally substituted heteroaryl wherein said heteroaryl is selected from pyrazolyl, isoxazolyl, pyrimidinyl, benzofuranyl, pyrazolo[1,5-a]pyrimidinyl, 1-azaindoliziny, s-triazolo[1,5-a]pyrimidinyl, imidazo[2,1-b]thiazolyl, thieno[3,2-b]pyridinyl, and said substituent is 1 to 3 groups independently selected from furanyl, pyridyl, benzyl, phenyl optionally substituted with halogen, C_1 -4alkyl, C_3 -6cycloalkyl, trifluoromethyl, halogen, and C_1 -4alkoxy.

9. **(currently amended)** A compound of Claim 6-1 having the formula Ia(2) and pharmaceutically acceptable salts thereof:




Ia(2)

wherein D is $C(O)NR^dR^4$, wherein R^d is H and R^4 is selected from (1) C_1 -4alkyl substituted with a group selected from halogen, OR^a , CO_2R^a , $NHCOR^a$, NR^dRe and $C(O)NR^dRe$; (2) optionally substituted heteroaryl- C_1 -4alkyl wherein heteroaryl is selected from azaindoliziny, imidazolyl, imidazolyl, benzimidazolyl, pyrazinyl, pyridyl, indolyl, triazolyl, thiazolyl, imidazo[1,2-a]pyridyl, imidazo[1,2-a]pyrimidinyl, imidazo[2,1-b]thiazolyl, and pyrazolo[1,5-a]pyrimidinyl; (3) optionally substituted heterocyclyl- C_1 -4alkyl wherein heterocyclyl is selected from tetrahydropyranyl, tetrahydrofuranyl and dioxanyl; (4) optionally substituted heterocyclyl selected from pyrrolidinyl and piperidinyl; (5) CO_2R^a ; (6) C_3 -6cycloalkyl; and (7) optionally substituted phenyl- C_1 -4alkyl; or R^d and R^4 together with the nitrogen atom to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR^g , O, S and SO_2 , wherein said ring is optionally

fused to a benzene or a 5- or 6-membered heteroaryl ring, and said substituent is 1 or 2 groups independently selected from OR^a, halogen, C₁-4alkyl, NR^dRe, NR^dCO₂R^a, and oxo.

10. **(original)** A compound of Claim 9 wherein R^d is H and R⁴ is selected from (1) C₁-4alkyl substituted with NR^dRe or C(O)NR^dRe, wherein for both groups R^d and Re together with the nitrogen to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR^g, O, S and SO₂, and wherein said substituent is 1 or 2 groups independently selected from OR^a, halogen, C₁-4alkyl and oxo; (2) heterocyclyl or heterocyclyl-C₁-4alkyl wherein said heterocyclyl is selected from pyrrolidinyl, 1,4-dioxanyl, and tetrahydropyranyl; and (3) heteroaryl-C₁-4alkyl optionally substituted with 1 to 3 C₁-4alkyl groups, wherein said heteroaryl is selected from imidazolyl, 1-azaindoliziny, imidazo[2,1-b]thiazolyl, and pyrimidinyl.

11. **(currently amended)** A compound of Claim 7-1 having the formula Ia(3) an pharmaceutically acceptable salts thereof:



wherein ~~D~~ is C(O)OR⁴, and R⁴ is selected from (1) C₂-4alkyl substituted with NR^dRe or C(O)NR^dRe in which, for these two groups, R^d and Re together with the nitrogen atom to which they are attached complete an optionally substituted 5- or 6-membered saturated ring having 0 to 1 additional ring heteroatom selected from NR^g, O, S and SO₂, and wherein said substituent is 1 or 2 groups independently selected from OR^a, halogen, C₁-4alkyl and oxo; (2) heterocyclyl-C₁-4alkyl optionally substituted with 1 to 3 groups independently selected from C₁-4alkyl and oxo, wherein heterocyclyl is selected from tetrahydropyranyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, oxazolidinyl, dioxanyl, and dioxolanyl; (3) furanyl-C₁-4alkyl; and (4) phenyl-C₁-4alkyl.

12. **(canceled)**

13. **(original)** A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

14. **(currently amended)** ~~Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament useful in~~ A method for the treatment or prevention of diseases or disorders mediated through the bradykinin receptor pathway which comprises administering to a patient in need thereof a compound of formula I or a pharmaceutically acceptable salt thereof.

15. **(currently amended)** The ~~use~~ method of Claim 14 wherein said disease or disorder is selected from neuropathic pain, acute pain and inflammatory pain.